Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32. Efficacy will be analyzed by: * skin prick testing * grass pollen inhalation challenge * antibody responses. In addition, the safety of subcutaneous application of BM32 will be evaluated.
Epistemonikos ID: b59bcd6567f94e49e8689d8c742a12f0432a7f95
First added on: May 10, 2024